On Oct. 20-22, the 5th International Molecular Imaging Symposium (IMIS 2023)- the Xiamen University, also known as the Innovative Radiopharmaceutical Development and Clinical Transformation Seminar were held grandly. As an influential and leading event in the field of molecular imaging, this forum brings together more than 500 industry elites, including academicians, experts, physicians, and entrepreneurs, to deliver keynote speeches, participate in professional conferences, and discuss the development direction of molecular imaging.
Yantai Lannacheng Biotechnology Co., Ltd. (referred to as "LNC"), a subsidiary of DC PHARMA, attended the meeting under the leadership of Prof. Chen Xiaoyuan, the Co-founder and Chief Scientific Officer of LNC, Mr. Wu Xiaoming, the General Manager of LNC, Prof. Zhang Jingjing, the Chief Medical Officer of LNC, the Assistant Professor of National University of Singapore. At the Seminar on Innovative Radiopharmaceutical Development and Clinical Translation, LNC was recognized by industry peers for its cutting-edge technology and innovative research achievements in the field of nuclide diagnosis and treatment.
—— Taking the conference as the media for succeed ——
On the afternoon of the 20th, nuclear medicine experts, scholars, industry authorities, and clinicians in the field of nuclear medicine from all over the country come to the Seminar on the Innovative Radiopharmaceuticals Development and Clinical Translation, jointly discussed the cutting-edge progress of radiotheranostics. The meeting was fully booked, with four industry big shots presiding over the meeting: Prof. Chen Xiaoyuan from LNC; Prof. Wang Jing, Director of Department of the Nuclear Medicine at Xijing Hospital of the Air Force Medical University and Chairman of the Nuclear Medicine Branch of the Chinese Medical Association; Prof. Li Biao, Director of Department of Nuclear Medicine of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; and Prof. Zhu Xiaohua, Director of Department of Nuclear Medicine at Tongji Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology, and other professors and experts shared the theme.
Prof. Chen Xiaoyuan and Prof. Wang Jing chaired the meeting
Prof. Li Biao and Prof. Zhu Xiaohua chaired the meeting
Prof. Yu Fei, Deputy Secretary of the Party Committee of the Tenth People's Hospital of Shanghai and Director of the Institute of Nuclear Medicine at Tongji University-"Alpha Immunotherapy " for Tumor Based on α Radionuclide.
Prof. Kang Fei, Deputy Director of Department of Nuclear Medicine, Xijing Hospital, the Air Force Medical University-- Development of Tumor KRAS Mutation Targeted PET Probe.
Prof. Lan Xiaoli, Director of the Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology- 68Ga-HX01, a Dual-targeted Imaging Agent for Tumor Neovascularization - Development and Clinical Application with Transformation.
Prof. Hu Shuo, Deputy Director of the Department of Nuclear Medicine at Xiangya Hospital Affiliated to Central South University - The Value of Multimodal Molecular Imaging in the Diagnosis and Treatment of Prostate Cancer.
Prof. Zhang Xianzhong, Head of Radiopharmaceuticals in the Department of the Nuclear Medicine of Peking Union Medical College Hospital - Fundamentals and Innovation of Oncology Radiopharmaceuticalss.
Prof. Miao Weibing, Director of the Department of Nuclear Medicine at the First Affiliated Hospital of Fujian Medical University - Clinical Transformation of 68Ga-FAPI-RGD.
Prof. Zhang Jingjing shared the development trend of integrated diagnosis and treatment, especially the clinical application experience of PRRT therapy targeting SSTR2, PSMA, and other targets. She stated that SSTR2 and PSMA, as targets with rich clinical application experiences, have brought new hope for patients with advanced neuroendocrine tumors and prostate cancer. In addition, she also exchanged cutting-edge experience in nuclear medicine with long half-life isotope 64Cu, as well as the combined application of 177Lu and 225Ac.
Prof. Zhang Jingjing - Radiotherapeutics for Precision Oncology: Clinical Experience with Novel Radioligands.
Prof. Chen Haojun, Deputy Chief Physician of the Department of Nuclear Medicine at the Department of Nuclear Medicine & Minnan PET Center, First Affiliated Hospital of Xiamen University, gave high praise to the FAP targets at the meeting. He stated that the IIT results of 18F-LNC1005 conducted at the First Affiliated Hospital of Xiamen University showed that its diagnostic capacity in gastrointestinal tumors was significantly better than 18F-FDG. He also highly praised the therapeutic effect of 177Lu-LNC1004 and was confident in the broad clinical application prospects of FAP targets.
Prof. Chen Haojun - Optimization Strategy and Clinical Transformation of Targeted FAP Radioprobes.
Experts and scholars have conducted extensive discussions on the theme of innovative radiopharmaceutical development and clinical translation, which brought profound inspiration and enlightenment to the participants.
At the meeting, Mr. Wu Xiaoming gave a detailed introduction to LNC's innovative radiopharmaceuticals, with a focus on LNC and its R&D pipeline for nuclear medicine diagnosis and treatment products, showcasing LNC's innovative capabilities and technological strength in the fields of nuclear medicine and radiotheranostics.
—— Masters Gathering, Academic Exchange ——
On 21st morning, Prof. Chen Xiaoyuan presided over the opening ceremony and announced the official start of the meeting.
During the keynote speech of the conference, Prof. Chen Xiaoyuan gave a special report entitled Cancer Radiotherapeutics. He took the R&D process of several marketed radionuclide therapy drugs as examples to systematically explain the key points of drug R&D. In addition, the progress and important clinical research results of 177Lu-LNC1003, 177Lu-LNC1004, and 177Lu-LNC1011 were shared, and many of LNC's internationally leading projects were introduced to industry experts again, which were fully recognized by industry experts.
—— Share experiences to Build Consensus ——
On the afternoon of the 21st, a number of domestic and foreign experts and scholars have given keynote speeches on the meeting of Radiopharmaceuticals Development and Clinical Translation.
Prof. Zhang Jingjing shared the research process of FAP-targeted therapeutic drugs, from the earliest 177Lu-FAPI-2286 to EB-modified 177Lu-LNC1004, etc. Using human data as an example, she presented the surprising clinical efficacy of FAP-targeted radioactive in vivo therapeutic drugs.
Prof. Chen Haojun shared his clinical research experience that the FAP-targeted PET imaging is significantly better than FDG. For DTC patients who still progressed after TKI treatment, the investigator conducted a 3+3 dose escalated study design by using the 177Lu-LNC1004 injection. The study results determined the clinical safety dose and achieved a good clinical benefits and controllable safety, bringing new hope to patients.
This academic forum has built a platform to explore new directions, and is committed to injecting strong momentum into the development of molecular imaging in China. The outstanding performance of LNC’s products at the conference once again proved their innovative ability and technological strength in the fields of nuclear medicine and radiotheranostic.
LNC was jointly founded by DC PHARMA and Professor Chen Xiaoyuan, a top expert in molecular imaging and nanomedicine, in 2021. Adhering to the concept of "Innovation-driven Micro Radiotheranostics R&D, Benefit People from Precision Therapy", LNC is focusing on the construction of a globally leading integrated diagnosis and therapy innovation platform on cancer nuclear medicine R&D. Next, LNC will continue to rely on DC PHARMA's strong and sound production and research system for the entire nuclear medicine industry chain, strengthen innovation, providing precision diagnosis and therapeutic methods for cancer patients and promoting the development of nuclear medicine in the world.
